Cyclophosphamide trials for Anatomic Stage II Breast Cancer AJCC v8

All Cyclophosphamide trials · All Anatomic Stage II Breast Cancer AJCC v8 trials

Phase breakdown

Recruiting trials studying Cyclophosphamide for Anatomic Stage II Breast Cancer AJCC v8

• Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
  NCT06058377 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 554 locations
• Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
  NCT06042569 · Phase: Phase 2 · Ages: 65 Years and older · Sex: All (male and female) · 3 locations
• Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
  NCT07016399 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
  NCT05929768 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 963 locations

Common questions

How many trials study Cyclophosphamide for Anatomic Stage II Breast Cancer AJCC v8?

4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.